Clinical Trials Browser

Phase 1/2 × ALT-803 × 90 days × Clear all

NCT05642195 2026-03-18

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase 1/2 Suspended

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06149481 2026-03-09

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06253494 2026-03-03

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT02523469 2026-02-17

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1/2 Completed

67 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung